
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health has demonstrated robust financial performance, with a year-over-year revenue growth of 7% despite challenging comparisons, positioning the company favorably in the liquid biopsy market. With over 50% market share in comprehensive genomic profiling and a projected increase in test frequency, particularly with the Reveal MRD test, Guardant is well-positioned for significant long-term growth. Additionally, the recent attainment of reimbursement coverage for its Reveal and Shield tests is expected to enhance average selling prices and drive volume growth, further strengthening the company's financial outlook.
Bears say
Guardant Health's stock outlook appears negative due to the potential for decreasing reimbursement, which could adversely affect average selling prices and overall revenues. The company's reliance on favorable reimbursement dynamics is further underscored by the pending PAMA regulations that could lead to a significant one-time revenue decline of approximately $100 million. Additionally, uncertainties in the regulatory landscape for multi-cancer early detection (MCED) tests pose risks to achieving necessary reimbursements, potentially hindering market adoption of Guardant's assays.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares